Upload
pharma-intelligence
View
11
Download
1
Embed Size (px)
Citation preview
Pharma R&D Annual Review 2017
CLICK HERE FOR MORE INFO
REQUEST A DEMO
FIND OUT MORE HERE
Pharma, like the movies, is getting bigger and bolder, growing by pretty much every measure in 2016. Here is our quick guide to the most important plots, twists and actors in today’s biopharmaceutical marketplace.
Pharma R&D Annual Review 2016
WHAT A PERFORMANCE!
14,872 8.4%
pipeline projects in 2017
increase on corresponding figure from 2016
increase through 2015–16and 8.8% the previous year11.5%
The 2016 Global Pipeline
Preclin Phase I Phase II Phase III Pre-reg Registered Launched Suspended
6861
7493
1856
2064
2261
2357 95
4
197
220
102
116
1273
1395
70 79
1025
The 2017 pipeline by phaseBaby boom leads the way, but growth throughout the family
Preclinical
INCREASE INCREASE INCREASE
Phase III
INCREASEin projects
(up by 632 drugs) in projects
(up by 208 drugs) in projects
(up by 96 drugs) in projects
(up by 71 drugs)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
15000
8000
0
2016 2017
Distribution of R&D CompaniesWhere Is The Action Taking Place?
2
3
4
5
6
7
8
9
10
GlaxoSmithKline 250 (242)
Pfizer 232 (217)
Merck & Co. 229 (223)
Johnson & Johnson 214 (227)
AstraZeneca 213 (231)
Roche 206 (211)
Sanofi 193 (199)
Bristol-Myers Squibb 144 (136)
Takeda 141 (137)
Novartis sits at the top of the tree. The Swiss conglomerate’s ascendancy to pole position is compounded by the fact that it originated a greater proportion of its pipeline itself compared to GSK.No. of Drugs in Pipeline 2017 (2016): 251(240)
47% 3% Germany3% France6% UK
19%Asian firms now accountfor 19% of companies, up from 16% last year, and driven not only by further expansion in China, but also by general growth throughout the region.
Asia companies up from16% a year ago
USA Down 1%from 2016
R&D Activity
1
11.1%
Anticancer
Biotechnology
Neurological
Anti-Infective
Reformulations
Alimentary/Metabolic
Musculoskeletal
Cardiovascular
Immunological
Dermatological
Sensory
Blood & Clotting
Genitourinary
Hormonal
Antiparasitic
4176
25132542
22212468
20802132
19992149
14991574
950962
869917
831911
855845
725797
608
597630
254275
121128
652
4845
40514481
2016 2017
16.0%INCREASE
Drugs in the pipelinewith a cancer focus
32.6%Drugs in development that have an oncological target
Anti-infectives
GROWTH
Anticancer, other2231 Projects
Anticancer, immunological2001 Projects
TOP TWO THERAPIES BASED ON PHARMAPROJECTS CATEGORIES
As biologicals proliferate, is the small molecule becoming a dinosaur?
In synthetic chemicals(Small molecules)
1
2
3
4
5
6
7
8
9
Chemical, synthetics
Origin
Biological, protein, antibody
Biological, protein, recombinant
Biological, protein
Chemical, synthetic, peptide
Biological, virus particles
Biological, cellular
Biological, nucleic acid, viral vector
Chemical, synthetic, nucleic acid
10 Biological, cellular, autologous
7,855 (7,540)
No of Active drugs 2017 (2016)
1,687 (1,466)
861 (892)
545 (439)
468 (434)
367 (303)
352 (210)
329 (297)
323 (301)
251 (214)
4.2%INCREASE
Monoclonal antibody-based drugs
15.1%INCREASE
The industry is involved in transferring a significant proportion of its eggs
into the biotech basket.
BIOTECH-DERIVED DRUGSNOW APPEAR IN OVER ATHIRD OF R&D ACTIVITY
RISE IN NUMBERS OF DRUGS RECEIVING ORPHAN DRUG STATUSOR AN EXPEDITED REVIEW DESIGNATION 2014–2016
2014 2015 2016
There were slightly fewer orphan drug statuses granted than during the previous year.
Orphan Drug Status Granted Expedited Review Status Granted
326 394 182 369 188
As the curtain falls on another year of pharma
IN THE LIMELIGHTTop 25 Therapies
157
1 2
Top 10 PharmaCompanies
BY SIZE OF PIPELINE
Top 10 Origins ofPipeline Drugs
BY NUMBER OF ACTIVE DRUGS
Big beasts still dominate, but Novartis is the new king of the jungle
USA
Rest of Europe
Rest of Asia Pacific
China
UK
Canada
Japan
Germany
France
C & S America/Africa
Respiratory
47%
11%
5%
3%
16%
6%
5%
3% 3% 1%
48%
9%
4%
3%
2%
18%
5%
5%
3% 3%
2016 2017
16% The Rest of Europe
Darwinian forces mean pharma’s creatures must find their niches
So it would seem that, for yet another year, the take-home message on pharma R&Dcan be summed up most simply as: there’s more of it than ever.
Survival of the fittest
Phase II
Top Companies
The pharma forest is teeming with lifeTotal R&D pipeline size16,000
14,000
12,000
10,000
8,000
6,000
4,000
2,000
02001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Source: Pharmaprojects®, January 2017
Pharma R&D By Numbers
Welcome to Pharmaprojects’ 2017 review of trends in pharmaceutical R&D
9.2% 11.2% 7.4% 4.2%
Types of pipeline drugs
Phase I